Trial · NCT04910685
Registered outcomes45
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 45
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs) | Up to 12 weeks | |
| Primary | Part 1: Mean change from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS) | Baseline, Week 13 | |
| Primary | Part 2: Mean change from baseline in ISM-SAF TSS | Baseline, Week 49 | |
| Primary | Part 3: Number of participants with Adverse Events (AEs) | Up to 5 years | |
| Primary | Part 3: Change from baseline in ISM-SAF TSS | Baseline up to 5 years | |
| Secondary | Part 1: Change from baseline in serum tryptase | Baseline, Week 13 | |
| Secondary | Part 1: Change from baseline in KIT D816V allele fraction in blood | Baseline, Week 13 | |
| Secondary | Part 1: Change from baseline in Bone Marrow (BM) mast cells | Baseline, Week 13 | |
| Secondary | Part 1: Mean change from baseline in ISM-SAF individual symptom scores | Baseline, Week 13 | |
| Secondary | Part 1: Time to achieve 30% reduction from baseline in ISM-SAF TSS | Baseline up to Week 13 | |
| Secondary | Part 1: Time to achieve 30% reduction from baseline in ISM-SAF domain scores | Baseline up to Week 13 | |
| Secondary | Part 2: Proportion of participants achieving normalized tryptase | Baseline up to Week 49 | |
| Secondary | Part 2: Proportion of participants who achieve an undetectable level or at least a 50% reduction in KIT D816V Variant Allele Frequency (VAF) | Baseline up to Week 49 | |
| Secondary | Part 2: Proportion of participants achieving symptom control as defined by achieving mild symptoms | Baseline up to Week 49 | |
| Secondary | Part 2: Mean percent change from baseline in Bone Mineral Density (BMD) | Baseline, Week 49 | |
| Secondary | Part 2: Mean change from baseline in the annualized rate of anaphylaxis events | Baseline, Weeks 25 to 48 | |
| Secondary | Part 2: Mean change from baseline in Quality of Life (QoL) scores | Baseline, Week 49 | |
| Secondary | Part 2: Mean change from baseline in ISM-SAF domain scores | Baseline, Week 49 | |
| Secondary | Part 2: Number of participants with AEs | Up to Week 49 | |
| Secondary | Part 2: Proportion of participants with a 50% reduction in ISM-SAF TSS | Baseline, Weeks 24 and 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04910685/registered